• MeSH
• Interferons immunology   isolation & purification   MeSH
• Molecular Structure MeSH
• Mice MeSH
• Check Tag
• Mice MeSH

• MeSH
• Biological Evolution MeSH
• Homeostasis MeSH
• Interferons physiology   MeSH
• Nucleic Acids MeSH

• MeSH
• Interferons immunology   therapeutic use   MeSH
• Publication type
• Congress MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• alergologie a imunologie

• MeSH
• Interferons physiology   classification   MeSH

• MeSH
• Dipyridamole administration & dosage   MeSH
• Interferons blood   MeSH
• Humans MeSH
• Check Tag
• Humans MeSH

• MeSH
• Interferons biosynthesis   MeSH
• Leukocytes immunology   MeSH
• In Vitro Techniques MeSH
• Ultrasonics MeSH

• MeSH
• Immunologic Techniques MeSH
• Interferons analysis   biosynthesis   MeSH
• Rats MeSH
• Cells, Cultured MeSH
• Viral Interference MeSH
• Vaccinia virus MeSH
• Check Tag
• Rats MeSH

• MeSH
• Interferons immunology   MeSH
• Leukocytes MeSH

• MeSH
• Antiviral Agents MeSH
• Interferons physiology   MeSH
• Lymphokines MeSH

V posledních měsících bylo uvedeno na trh další léčivo pro relaps remitentní roztroušenou sklerózu (RS). Jedná se o tzv. „PEGylovaný“ interferon beta-1a. Jde o původní molekulu interferonu beta-1a, která je známá již dvě desetiletí v léčbě RS, ale nově je opatřena molekulou polyetylenglykolu (PEG), což jí dává některé vlastnosti zlepšující celkový profil původní molekuly interferonu. Článek shrnuje profil účinnosti na klinické i radiologické parametry i bezpečnostní profil léku, které vyplynuly z klíčové klinické studie ADVANCE a též navazující studie ATTAIN. PEGylovaný interferon beta-1a nyní rozšiřuje portfolio léků DMD (disease modifying drugs) 1. linie, které jsou používány pro léčbu klinicky izolovaného syndromu nebo relaps remitentní RS.

Another drug for relapsing-remitting multiple sclerosis (MS) has been introduced into the market in recent months. It is the socalled“PEGylated” interferon beta-1a. It is the original interferon beta-1a molecule, which has been known in the treatment of MSfor two decades, but has newly been bound to a molecule of polyethylene glycol (PEG), which provides it with some propertiesimproving the overall profile of the original interferon molecule. The article summarizes the profile of efficacy on clinical andradiological parameters and the safety profile of the drug established by the pivotal clinical trial ADVANCE as well as by its extensionstudy, called ATTAIN. PEGylated interferon beta-1a has now expanded the portfolio of first-line disease-modifying drugs(DMDs) used in the treatment of clinically isolated syndrome or relapsing-remitting MS.

• Keywords
• studie ADVANCE, NEDA, pegylovaný interferon beta-1a,
• MeSH
• Interferon beta-1a * administration & dosage   adverse effects   therapeutic use   MeSH
• Clinical Trials as Topic MeSH
• Humans MeSH
• Polyethylene Glycols * pharmacology   therapeutic use   MeSH
• Recurrence MeSH
• Multiple Sclerosis * drug therapy   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH